SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study.
Aino Latva-RaskuEleni RebelosJouni TuiskuRichard AarnioAchol A BhowmikHelmi KeskinenSanna LaurilaMinna Lahesmaa-HattingLaura PekkarinenHenrik IsacksonAnna Kaarina KirjavainenJukka KoffertKerstin HeurlingLauri NummenmaaEleuterio FerranniniJonas OldgrenJan OscarssonPirjo NuutilaPublished in: Diabetes care (2024)
Six weeks of treatment with dapagliflozin increases skeletal muscle and brain FA uptake, partly driven by a rise in free FA availability. This finding is in accordance with previous indirect measurements showing enhanced FA metabolism in response to SGLT2 inhibition and extends the notion of a shift toward increased FA use to muscle and brain.
Keyphrases
- skeletal muscle
- positron emission tomography
- placebo controlled
- resting state
- double blind
- white matter
- computed tomography
- insulin resistance
- fatty acid
- functional connectivity
- cerebral ischemia
- clinical trial
- study protocol
- multiple sclerosis
- pet ct
- randomized controlled trial
- pet imaging
- phase iii
- adipose tissue
- subarachnoid hemorrhage
- phase ii
- brain injury
- open label
- rectal cancer